Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg. In this regard, the company has enclosed a press release on 23rd April 2021.
The above information is a part of company’s filings submitted to BSE.